Skip to Content

Sprimeo HCT

Active Substance: aliskiren / hydrochlorothiazide
Common Name: aliskiren / hydrochlorothiazide
ATC Code: C09XA52
Marketing Authorisation Holder: Novartis Europharm Ltd.
Active Substance: aliskiren / hydrochlorothiazide
Status: Withdrawn
Authorisation Date: 2011-06-23
Therapeutic Area: Hypertension
Pharmacotherapeutic Group: Agents acting on the renin-angiotensin system

Therapeutic Indication

Treatment of essential hypertension in adults.

Sprimeo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone.

Sprimeo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.

The marketing authorisation for Sprimeo HCT has been withdrawn at the request of the marketing-authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.